Several other research firms have also issued reports on GERN. Cantor Fitzgerald increased their price target on shares of Geron from $3.00 to $4.00 and gave the stock an overweight rating in a research report on Monday, June 1st. B. Riley increased their price target on shares of Geron from $3.50 to $4.00 and gave the stock a buy rating in a research report on Friday, May 29th. Needham & Company LLC reissued a buy rating and issued a $3.00 price target on shares of Geron in a research report on Wednesday, June 17th. Zacks Investment Research raised shares of Geron from a hold rating to a strong-buy rating and set a $1.75 price target for the company in a research report on Tuesday, June 2nd. Finally, ValuEngine cut shares of Geron from a buy rating to a hold rating in a research note on Monday, March 16th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Geron currently has a consensus rating of Buy and an average target price of $3.29.
Shares of GERN opened at $2.18 on Tuesday. The company has a 50-day simple moving average of $1.74 and a 200-day simple moving average of $1.37. The firm has a market capitalization of $426.97 million, a P/E ratio of -5.59 and a beta of 1.75. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.93 and a current ratio of 7.93. Geron has a 52 week low of $0.75 and a 52 week high of $2.40.
Geron (NASDAQ:GERN) last posted its quarterly earnings results on Thursday, May 28th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.12) by $0.04. Geron had a negative net margin of 16,449.23% and a negative return on equity of 52.95%. The firm had revenue of $0.05 million during the quarter, compared to analyst estimates of $0.11 million. During the same quarter in the prior year, the business posted ($0.05) earnings per share. As a group, equities analysts forecast that Geron will post -0.28 earnings per share for the current year.
A number of institutional investors have recently modified their holdings of the business. State Street Corp grew its stake in Geron by 2.6% during the first quarter. State Street Corp now owns 3,733,115 shares of the biopharmaceutical company’s stock worth $4,442,000 after buying an additional 94,091 shares during the last quarter. Advisor Group Holdings Inc. bought a new stake in shares of Geron during the first quarter valued at approximately $84,000. Invesco Ltd. bought a new stake in shares of Geron during the first quarter valued at approximately $183,000. Two Sigma Investments LP grew its stake in shares of Geron by 74.2% during the first quarter. Two Sigma Investments LP now owns 1,594,434 shares of the biopharmaceutical company’s stock valued at $1,897,000 after purchasing an additional 679,373 shares during the last quarter. Finally, Two Sigma Advisers LP grew its stake in shares of Geron by 1,403.8% during the first quarter. Two Sigma Advisers LP now owns 668,608 shares of the biopharmaceutical company’s stock valued at $796,000 after purchasing an additional 624,146 shares during the last quarter. 30.64% of the stock is currently owned by hedge funds and other institutional investors.
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It holds rights to imetelstat, a telomerase inhibitor in Phase 2/3 clinical trials, which inhibits the uncontrolled proliferation of malignant progenitor cells in hematologic myeloid malignancies to reduce dysfunctional blood cell production and enable recovery of normal blood cell production.
Featured Article: What strategies should day traders use to execute a trade?
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.